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Abstract
It is important to characterize the temporal trajectories of disease-related
biomarkers in order to monitor progression and identify potential points of
intervention. These are especially important for neurodegenerative diseases, as
therapeutic intervention is most likely to be effective in the preclinical disease
stages prior to significant neuronal damage. Neuroimaging allows for the measure-
ment of structural, functional, and metabolic integrity of the brain at the level of
voxels, whose volumes are on the order of mm3. These voxelwise measurements
provide a rich collection of disease indicators. Longitudinal neuroimaging studies
enable the analysis of changes in these voxelwise measures. However, commonly
used longitudinal analysis approaches, such as linear mixed effects models, do
not account for the fact that individuals enter a study at various disease stages
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and progress at different rates, and generally consider each voxelwise measure
independently. We propose a multivariate nonlinear mixed effects model for esti-
mating the trajectories of voxelwise neuroimaging biomarkers from longitudinal
data that accounts for such differences across individuals. The method involves
the prediction of a progression score for each visit based on a collective analysis
of voxelwise biomarker data within an expectation-maximization framework that
efficiently handles large amounts of measurements and variable number of visits
per individual, and accounts for spatial correlations among voxels. This score
allows individuals with similar progressions to be aligned and analyzed together,
which enables the construction of a trajectory of brain changes as a function of
an underlying progression or disease stage. We apply our method to studying
cortical β-amyloid deposition, a hallmark of preclinical Alzheimer’s disease, as
measured using positron emission tomography. Results on 104 individuals with
a total of 300 visits suggest that precuneus is the earliest cortical region to
accumulate amyloid, closely followed by the cingulate and frontal cortices, then
by the lateral parietal cortex. The extracted progression scores reveal a pattern
similar to mean cortical distribution volume ratio (DVR), an index of global
brain amyloid levels. The proposed method can be applied to other types of
longitudinal imaging data, including metabolism, blood flow, tau, and structural
imaging-derived measures, to extract individualized summary scores indicating
disease progression and to provide voxelwise trajectories that can be compared
between brain regions.
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1. Introduction
It is important to characterize the temporal trajectories of disease-related
biomarkers in order to monitor progression and to identify potential points of in-
tervention. Such a characterization is especially important for neurodegenerative
diseases, as therapeutic intervention is most likely to be effective in the preclinical5
disease stages prior to significant neuronal damage. For example, in Alzheimer’s
2
disease, brain changes evident in structural, functional, and metabolic imaging
may occur more than a decade before the onset of cognitive symptoms (Bateman
et al., 2012), with cortical amyloid-β (Aβ) accumulation being one of the earliest
changes (Jack et al., 2013; Sperling et al., 2014a; Villemagne et al., 2013). Such10
brain changes can be measured using neuroimaging techniques and can be tracked
over time at the individual level via longitudinal studies.
Given the focus on preventing and delaying the onset of incurable neurodegen-
erative diseases, the emphasis of clinical trials has shifted to studying clinically
normal individuals with positive biomarkers, for example those exhibiting brain15
amyloid in the case of AD, in order to identify early intervention opportunities
in the preclinical stages of disease (Sperling et al., 2014b). It is important to de-
termine the temporal trajectories of hypothesized biomarkers in the early disease
stages in order to better understand their associations with disease progression.
Current neuroimaging methods allow for the characterization of the brain at20
the mm3 level, generating hundreds of thousands of measurements that can be
used as potential biomarkers of neurodegenerative diseases. Understanding the
temporal trajectories of these voxelwise measurements can provide clues into
disease mechanisms by identifying the earliest and fastest changing brain regions.
Changes in voxelwise neuroimaging measurements over time are commonly25
studied using linear mixed effects models (Bernal-Rusiel et al., 2012, 2013;
Ziegler et al., 2015). Univariate linear mixed effects models use time or age to
characterize changes in a single imaging measure. However, time or age may not
be the appropriate metric for measuring disease progression due to variability
across individuals. While covariates can be included in linear mixed effects30
models to account for this variability, choosing the correct set of covariates
is difficult and covariates generally have a more complicated association with
disease progression than the assumed linear relationship of linear mixed effects
models. Instead, this variability can be accounted for by aligning individuals
in time based on their longitudinal biomarker profiles within a multivariate35
framework. This is the premise of the Disease Progression Score method, which
has been applied to studying changes in cognitive and biological markers related
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to Alzheimer’s disease (Jedynak et al., 2012, 2014; Bilgel et al., 2014). It is
assumed that there is an underlying progression score (PS) for each subject visit
that is an affine transform of the subject’s age, and given this PS, it is possible40
to place biomarker measurements across a group of subjects onto a common
timeline. The affine transformation of age removes across-subject variability in
baseline biomarker measures as well as in their rates of longitudinal progression.
Each biomarker is associated with a parametric trajectory as a function of PS,
whose parameters are estimated along with the PS for each subject. This allows45
one to “stitch” data across subjects to obtain temporal biomarker trajectories
that fit an underlying model (Fig. 1).
Previous approaches have used certain cognitive measures, such as ADAS-
Cog (Caroli and Frisoni, 2010; Yang et al., 2011), MMSE (Doody et al., 2010) or
CDR-SB (Delor et al., 2013) as a surrogate for disease progression to delineate50
the trajectories of other AD-related cognitive measurements. These methods
operate with the assumption that disease progression is reflected by a single
cognitive measurement rather than a profile of multiple measurements, and
therefore are inherently limited in their characterization of disease evolution.
Younes et al. (2014) fitted a piecewise linear model to longitudinal data assuming55
that each biomarker becomes abnormal a certain number of years before clinical
diagnosis, and this duration was estimated for each biomarker to yield longitudi-
nal trajectories as a function of time to diagnosis. A quantile regression approach
was employed by Schmidt-Richberg et al. (2015) to align a sample of cognitively
normals and mild cognitively impaired (MCI) with a sample of MCI and AD,60
and then to estimate biomarker trajectories. These approaches assume that all
individuals are on a path to disease and require knowledge of clinical diagnosis.
Therefore, they are not suitable for studying the earliest changes in individuals
who have not converted to a clinical diagnosis. Donohue et al. (2014) applied a
self-modeling regression model within a multivariate framework to characterize65
the longitudinal trajectories of a set of cognitive, CSF, and neuroimaging-based
biomarkers. This approach allows for across-subject variability only in the age
of onset, not in progression speed. Models incorporating fixed effects as well
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as individual-level random effects have been proposed to study ADAS-Cog (Ito
et al., 2011; Schiratti et al., 2015b) and regional cortical atrophy (Schiratti et al.,70
2015b), and Schulam et al. (2015) used a spline model that incorporates longitu-
dinal clustering and modeling of individual-level effects to study trajectories of
scleroderma markers. These mixed effects models take into consideration each
measure separately rather than using them within a unifying framework. Others
have used event-based probabilistic frameworks to determine the ordering of75
changes in longitudinal biomarker measures as well as the appropriate thresholds
for separating normal from abnormal measures (Fonteijn et al., 2012; Young
et al., 2014). These methods characterize longitudinal biomarker trajectories
in a discrete framework rather than a continuous one. Schiratti et al. (2015a)
proposed an extension to their earlier approach to model multiple measures80
together. Biomarker trajectories are assumed to be identical except for a shift
along the disease timeline, and this assumption prevents hypothesis testing re-
garding rate of change across biomarkers. Furthermore, biomarkers are assumed
to be conditionally independent given the subject-level random effects, but
this assumption is not realistic when biomarkers are voxel-based neuroimaging85
measurements.
Here, we adapt the disease progression score principle to studying longitudinal
neuroimaging data by making substantial innovations to the progression score
model and parameter estimation procedure. First, voxelwise imaging measures
constitute the biomarkers in the model, and are analyzed together in a multi-90
variate framework. Studying progression at the voxel level rather than using
region of interest (ROI)-based measures allows for the discovery of patterns that
may not be confined within any given ROI. Second, since voxelwise imaging
measures have an underlying spatial correlation, we incorporate the modeling
of the spatial correlations among the biomarker error terms. Modeling spatial95
correlations makes the inference of the subject-specific progression scores less
susceptible to the inherent correlations among the voxels. Third, we incorporate
a bivariate normal prior on the subject-specific variables that define the relation-
ship between age and PS. The prior allows a better modeling of the variance
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within individuals and enables the incorporation of individuals with a single100
visit into the model fitting procedure. Fourth, instead of using an alternating
least-squares approach for parameter estimation as presented by Jedynak et al.
(2012), we formulate the model fitting as an expectation-maximization (EM)
algorithm, which guarantees convergence to a local maximum and allows for an
efficient model fitting framework for a large number of biomarkers. Finally, we105
present a statistical framework for comparing the onset and rate of progression
across different regions. This paper extends our previous approach for analyzing
longitudinal voxelwise imaging measures using the progression score framework
by incorporating a prior on the subject-specific variables, presenting a hypothe-
sis testing framework for determining biomarker ordering, and performing an110
extensive validation of the method (Bilgel et al., 2015c).
We first show using simulated data that the model parameters are estimated
accurately and that modeling spatial correlations improves parameter estimation.
We then apply the method to distribution volume ratio (DVR) images derived
from Pittsburgh compound B (PiB) PET imaging, which show the distribution115
of cerebral fibrillar amyloid. Models fitted using data for 104 participants with a
total of 300 PiB-PET visits reveal that the precuneus and frontal cortex show the
greatest longitudinal increases in fibrillar amyloid, with smaller increases in lateral
temporal and temporoparietal regions, and minimal increases in the occipital
cortex and the sensorimotor strip. Our results suggest that the precuneus is120
the earliest cortical region to accumulate amyloid. The results are consistent
across the two hemispheres, and the estimated PS agrees with a widely used
PET-based global index of brain amyloid known as mean cortical DVR. The
presented method can be applied to other types of longitudinal imaging data to
understand voxelwise trajectories and to quantify each individual scan against125
the estimated progression pattern.
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2. Method
2.1. Model
Our goal is to characterize the progression of disease or an underlying process
as measured using a collection of relevant biomarkers. Disease or process stage,130
as indicated by a progression score (PS), s, is intrinsically related to time t,
measured as the age of a subject. Since individuals differ in their onset and
rate of progression, the relationship between s and t varies across individuals.
We model the progression s as a linear function of time t for each individual
and allow for the prediction of separate slopes and intercepts to account for this135
variability across individuals.
Generally, there is a particular presentation of symptoms and biomarker
measurements at a given progression stage. Furthermore, as the disease or
process progresses, there is a particular temporal progression of the biomarkers.
In this work, we consider voxelwise PET measures as biomarkers and model140
the temporal trajectory of each biomarker, or voxel, as a linear function of the
progression s. Considering voxelwise neuroimaging measures as biomarkers may
appear unusual; however, these measures fit the NIH definition of a biomarker:
“a characteristic that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmacologic responses to145
a therapeutic intervention” (Biomarkers Definitions Working Group, 2001). As
illustrated in Figure 1, PS aligns longitudinal biomarker measures better than
age since it accounts for differences across individuals in rates as well as baseline
levels of progression. After this alignment in time, the estimated biomarker
trajectories can be compared on the common PS scale.150
In the following subsections, we describe the progression score model in detail.
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Figure 1: Illustration of the biomarker alignment concept in the progression score model. The
biomarkers we consider in this work are PET measures of cerebral amyloid across a total of
K ≈ 30, 000 voxels. Top: Progression score (PS) aligns longitudinal measures better than
age, and allows for the estimation of a trajectory for each biomarker/voxel (in gray). Bottom:
Estimated biomarker trajectories can be compared on the common PS scale.
2.1.1. Subject-specific model
The progression score sij for subject i at visit j is assumed to be an affine
transformation of the subject’s age tij :
sij = αitij + βi
= qTijui, (1)
where qij =
tij
1
, and ui =
αi
βi
. The subject-specific variables, αi and βi155
contained in the vector ui, are assumed to follow a bivariate normal distribution,
i.e., ui ∼ N2(m, V ), which are independent and identically distributed across
subjects. This model accounts for differences between subjects in the rate of
progression via α, and in the baseline levels of disease progression via β.
2.1.2. Subject-specific prior covariance model160
The prior covariance V is modeled as a 2× 2 unstructured covariance matrix.
Log-Cholesky parametrization of V , given by ν, ensures that V ≡ V (ν) is positive
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definite (Pinheiro and Bates, 1996). Let U =
U11 U12
0 U22
 be an upper triangular
matrix such that V = UTU . If the diagonal elements of U are constrained to be
positive, then this Cholesky decomposition is unique. To ensure that the diagonal165
elements of U are positive in an unconstrained optimization framework, we use
the natural logarithm of the diagonal elements of U as parameters. We then
vectorize the upper triangular elements (including the diagonal) of U to obtain
the parameter vector ν = [logU11 U12 logU22]
T , which uniquely parameterizes
V and ensures its positive definiteness.170
2.1.3. Biomarker trajectory model
The collection of K biomarker measurements form the K × 1 vector yij for
subject i at visit j. Longitudinal trajectories associated with these biomarkers
are assumed to be linear and parameterized by K × 1 vectors a and b:
yij = a sij + b+ ij . (2)
Here, a = [a1, a2, . . . , aK ]
T , b = [b1, b2, . . . , bK ]
T , and ij ∼ NK(0, R) is the
observation noise. ij are assumed to be independent and identically distributed
across subjects and visits.
2.1.4. Noise covariance model175
The matrix R is assumed to have the form R = ΛCΛ, where Λ is a diagonal
matrix with positive diagonal elements λ and C is a correlation matrix param-
eterized by ρ. This parameterization guarantees that R is a positive definite
matrix (Galecki and Burzykowski, 2013). For ease of notation, we let Λ ≡ Λ(λ),
C ≡ C(ρ), and R ≡ R(λ,ρ).180
When the biomarkers under consideration have a spatial organization, i.e.,
if they are voxelwise measurements from medical images, then the correlation
matrix C can be described as a function of the spatial distance d ≡ d(k, k′)
between pairs of voxels indexed by k and k′ as well as the spatial correlation
parameter ρ. Possible univariate parameterizations (i.e., ρ = ρ ∈ R) of C are185
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presented in Table 1. All of these spatial correlation functions ensure that C is
a valid correlation matrix (Galecki and Burzykowski, 2013).
Table 1: Spatial correlation functions.
Exponential Ckk′ = e
−d/ρ
Gaussian Ckk′ = e
−(d/ρ)2
Rational quadratic Ckk′ =
1
1+(d/ρ)2
Spherical Ckk′ =
(
1− 32 dρ + 12
(
d
ρ
)3)
1(d < ρ)
d ≡ d(k, k′) is the spatial distance between voxels indexed by k and k′.
2.1.5. Overall model
The overall model, diagrammatically summarized using plate notation in
Fig. 2, is described by the following equations:190
sij = q
T
ijui (3)
yij = a sij + b+ ij (4)
ui ∼ N2(m, V (ν)) (5)
ij ∼ NK(0, R(λ,ρ)). (6)
While this model is a mixed effects model since it incorporates the fixed effects
a,b as well as the individual-level random effects ui, and is nonlinear in the pa-
rameters, it departs from the form of the nonlinear mixed effects model described
by Lindstrom and Bates (1990). Therefore, instead of pursuing a restricted max-
imum likelihood approach, we use an expectation-maximization (EM) approach,195
as described below.
Let θ be the collection of model parameters m,ν,a,b,λ,ρ. The complete
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Figure 2: Probabilistic model of the progression score using plate notation. The progression
score sij establishes the link between age tij and the voxelwise observations yij . Circles
indicate variables, and known measures are shaded. Rectangles indicate that the same model
applies across visits (inner rectangle) and individuals (outer rectangle). Arrows indicate
dependencies between variables and parameters.
log-likelihood for the model is
`(y,u;θ) =
∑
i
`(yi,ui;θ) (7)
=
∑
i
log f(yi | ui;θ) + log f(ui;θ) (8)
= −1
2
∑
i,j
log |2piR| − 1
2
∑
i,j
(yij − Zijui − b)T R−1 (yij − Zijui − b)
−1
2
∑
i
log |2piV | − 1
2
∑
i
(ui −m)T V −1 (ui −m) , (9)
where Zij = aq
T
ij . yi is a vector of all biomarker measures stacked across all
visits of individual i, and yij is a vector of all biomarker measures for individual200
i at visit j. Given n individuals, we use the summation notation
∑
i,j as a
shorthand for
∑n
i=1
∑vi
j=1, where vi is the number of visits for individual i.
Since the marginal likelihood f(y; θ) involves an integral over all possible
values of ui, maximizing it directly is difficult. Therefore, we use the expectation-
maximization (EM) approach, where we consider the subject-specific variables205
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{ui} as hidden. EM allows us to reformulate the maximization problem in terms
of the complete log-likelihood `(y,u; θ). The observations y include biomarker
measurements {yij} at each visit. The unknown parameters are the subject-
specific variable distribution parameters m and ν, the trajectory parameters a
and b, and the noise covariance parameters λ and ρ.210
2.2. E-step
(y,u) are the complete data. Let θ′ = {m′,ν′,a′,b′,λ′,ρ′} be the previous
parameter estimates. By Proposition A.1, the E-step integral is proportional to∑
i
∫
Φ(u˜i; uˆ
′
i,Σ
′
i)` (yi, u˜i;θ) du˜i, where Φ is the multivariate normal probability
density function with mean
uˆ′i =
∑
j
Z ′Tij R
′−1Z ′ij + V
′−1
−1∑
j
Z ′Tij R
′−1(yij − b′) + V ′−1m′
 , (10)
and covariance Σ′i =
(∑
j Z
′T
ij R
′−1Z ′ij + V
′−1
)−1
. Note that for individuals with
a single visit,
∑
j Z
′T
ij R
′−1Z ′ij is a singular matrix. Considering ui as parameters,
as in Jedynak et al. (2012) or Bilgel et al. (2015c), is equivalent to assuming
that V has infinitely large diagonal elements (i.e., an uninformative uniform215
prior) such that its inverse disappears. Therefore, it is not possible to compute
uˆ′i for individuals having only one visit using this approach. On the other hand,
incorporation of a bivariate normal prior on the subject-specific variables ui
allows Eq. 10 to be computed for individuals with a single visit.
Evaluation of the E-step integral involves second moments of a Gaussian220
random variable. We ignore the terms that do not depend on θ as they will not
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be relevant in the maximization step and obtain:
Q
(
θ,θ′
)
= −1
2
∑
i,j
log |R|
−1
2
∑
i,j
(yij − Zijuˆ′i − b)TR−1(yij − Zijuˆ′i − b)
−1
2
∑
i,j
Tr
(
ZTijR
−1ZijΣ′i
)− 1
2
∑
i
log |V |
−1
2
∑
i
(uˆ′i −m)TV −1(uˆ′i −m)−
1
2
∑
i
Tr
(
V −1Σ′i
)
. (11)
2.3. M-step
Here, we provide the update equations for the EM algorithm obtained by
maximizing Q(θ,θ′) with respect to each parameter, and provide derivations225
for these update equations in the Appendix. The update equations depend on
previous parameter estimates θ′ = {m′,ν′,a′,b′,λ′,ρ′} as well as the progression
score estimates s′ij = q
T
ijuˆ
′
i, where uˆ
′
i is as given in Eq. 10:
a =
(
∑
i vi)
(∑
i,j yijs
′
ij
)
−
(∑
i,j yij
)(∑
i,j s
′
ij
)
(
∑
i vi)
(∑
i,j q
T
ijΣ
′
iqij + s
′2
ij
)
−
(∑
i,j s
′
ij
)2 , (12)
b =
(∑
i,j yij
)(∑
i,j q
T
ijΣ
′
iqij + s
′2
ij
)
−
(∑
i,j yijs
′
ij
)(∑
i,j s
′
ij
)
(
∑
i vi)
(∑
i,j q
T
ijΣ
′
iqij + s
′2
ij
)
−
(∑
i,j s
′
ij
)2 ,(13)
m =
1
n
∑
i
uˆ′i, (14)
ν = arg max
ν
Q(θ,θ′), (15)
λ, ρ = arg max
λ,ρ
Q(θ,θ′). (16)
Note that if C is fixed to be the identity matrix, a closed form solution for λ
exists, as given in Equation A.15. Once the optimal parameters are found, the230
subject-specific variables are predicted using Eq. (10).
2.4. Parameter standardization
As described in Proposition A.2, there are certain reparameterizations that
yield identical models. For example, one can multiply the trajectory slope
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parameters by 2 and divide all progression scores by 2 (which is achieved by235
dividing all α and β values by 2) without altering the model. This is the scaling
degree of freedom. There is also a translation degree of freedom. We account for
these degrees of freedom and anchor the model by calibrating the progression score
scale. We calibrate such that baseline PS has a mean of 0 and a standard deviation
of 1. This involves replacing the model parameters {m, V (ν),a,b, R(λ,ρ)}240
with
wm+
0
z
 , w2V (ν), 1wa,b− zwa, R(λ,ρ)
, where − zw = 1n∑i si1 is the
mean progression score at baseline, and 1w =
√
1
n
∑
i
(
si1 − 1n
∑
i si1
)2
is the
standard deviation of baseline progression scores. We standardize the subject-
specific estimates αi, βi, and sij accordingly: α
∗
i = wαi, β
∗
i = wβi + z, and
s∗ij = wsij + z. This reparametrization yields a PS scale where 0 corresponds to245
the sample average at baseline and the variance of PS at baseline is 1.
2.5. Implementation details
We first fit the model assuming that C = IK×K and Λ is a diagonal matrix
with positive elements λ. We denote the estimated Λ in this model as Λˆ. The
estimates obtained from this model for the parameters a,b,m, V are used as250
initializations in the model where C = C(ρ). In this model where correlations are
taken into account, we assume that Λ = λΛˆ, where λ is an unknown parameter
to be estimated. The spatial correlation function among those presented in
Table 1 that results in the highest log-likelihood value is chosen for the final
model.255
The EM algorithm is implemented in MATLAB 8.1 and Statistics Toolbox 8.2
(The MathWorks Inc., Natick, MA). Our code is freely available online.1
2.6. Confidence intervals
We use bootstrapping via Monte Carlo resampling to estimate confidence
intervals for each model parameter. We sample with replacement from the260
1https://www.iacl.ece.jhu.edu/Resources
14
original collection of subjects to generate a new dataset containing an equal
number of subjects and fit the model on this generated sample. This sampling and
fitting procedure is repeated to generate bootstrap estimates. We then compute
95% confidence intervals for each parameter across the bootstrap estimates. In
the bootstrap experiments, we fix the value of ρ at its estimate on the whole265
sample to enable faster computation.
2.7. Comparison to linear mixed effects model
We compared our model to a linear mixed effects (LME) model that included
random intercepts and slopes at each voxel. The LME model for subject i, visit j
and voxel k is given by
yijk = (ηk + ηik)tij + (γk + γik) + εijk, (17)
where
ηk
γk
 are the fixed effects,
ηik
γik
 ∼ N (0,Ξk) are the random effects and
εijk ∼ N (0, σ2k) is the observation noise. We used the LME implementation in
MATLAB Statistics Toolbox 8.2.270
2.8. Simulated data set
We simulated visits such that the sample was similar to our PET data in
terms of number of visits per subjects and age range. We generated a data set
with 100 individuals, each with up to 7 visits with 5× 5× 5 images with 4 mm
isotropic voxels. We fixed the ground truth values of the model parameters
θ = {m,ν,a,b,λ, ρ} at values close to those we observed in exploratory models
fitted to DVR data. We generated ui from a bivariate normal distribution
with mean m and variance V (ν). The progression score for each visit was then
computed as sij = q
T
iju, and observations were generated using the PS model.
We performed 1000 bootstrap iterations to obtain 95% confidence intervals for
each parameter and subject-specific variable. We computed the cosine similarity
for each variable for each bootstrap experiment using
φT φ̂
‖φ‖2‖φ̂‖2
, (18)
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where φ̂ is the estimate of the variable of interest (a,b,α,β, or s) and φ is the
corresponding ground truth value. A value of 1 indicates a perfect estimate.
2.9. Amyloid imaging data set
We used longitudinal positron emission tomography (PET) data for partic-275
ipants from the Baltimore Longitudinal Study of Aging (Shock et al., 1984)
neuroimaging substudy (Resnick et al., 2000). Participant demographics are
presented in Table 2. Starting in 2005, amyloid-beta (Aβ) PET scans were ac-
quired on a GE Advance scanner over 70 minutes following an intravenous bolus
injection of Pittsburgh compound B (PiB), yielding dynamic PET scans with 33280
time frames. PET images were reconstructed using filtered backprojection with
a ramp filter, yielding a spatial resolution of approximately 4.5 mm full width at
half max at the center of the field of view (image matrix = 128× 128, 35 slices,
pixel size = 2× 2 mm, slice thickness = 4.25 mm).
The frames of each dynamic PiB-PET scan were aligned to the average of285
the first two minutes to remove motion (Jenkinson et al., 2002). For registra-
tion purposes, we obtained static images by averaging the first 20 minutes of
the dynamic PiB-PET scan. Follow-up PiB-PET scans were rigidly registered
onto the baseline PiB-PET within each participant using the 20-minute average
images. Baseline magnetic resonance images (MRIs) were rigidly registered onto290
their corresponding 20-minute PiB-PET average, and their FreeSurfer segmen-
tations (Dale et al., 1999; Desikan et al., 2006) were transformed accordingly.
Distribution volume ratio (DVR) images were calculated in the native space
of each PiB-PET image using the simplified reference tissue model with the
cerebellar gray matter as reference tissue (Zhou et al., 2003). The MRIs coreg-295
istered with the PET were deformably registered (Avants et al., 2008) onto a
study-specific template (Avants et al., 2010; Bilgel et al., 2015b) and transformed
to 4 mm isotropic MNI space using a pre-calculated affine transformation. The
resulting mappings were applied to the DVR images that have been registered
to baseline to bring them into the MNI space. We used all voxels within the300
brain mask in the MNI space to fit the PS model.
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Table 2: Participant demographics. MCI = mild cognitive impairment, SD = standard
deviation.
Characteristic N = 104
Baseline age in years, mean (SD) 77.0 (7.9)
Range 55.7–93.4
Female, n (%) 48 (46%)
PiB-PET scans, n 300
PiB-PET per subject, n 2.9 (1.8)
Range 1–7
Years between first and last scan, mean (SD) 3.3 (2.9)
Range 0.0–9.0
Mean cortical DVR at last visit (SD) 1.12 (0.19)
PiB+ at last visit, n (%) 42 (40%)
MCI diagnosis at last visit, n (%) 3 (3%)
Dementia diagnosis at last visit, n (%) 4 (4%)
Mean cortical DVR is a widely used measure obtained from PiB-PET images
for quantifying the level of brain amyloid. We computed mean cortical DVR for
each PiB-PET image by averaging the voxelwise DVR values across cingulate,
frontal, parietal, lateral temporal, and lateral occipital cortices, excluding the305
sensorimotor strip. We used a mean cortical DVR threshold of 1.06, which was
computed from a two-class Gaussian mixture model fitted on baseline measures,
to separate individuals into PiB- and PiB+ groups, as described in Bilgel et al.
(2015a).
2.10. Hypothesis testing310
The confidence intervals obtained via bootstrapping allow for hypothesis
testing. For the amyloid images, we focus on studying the precuneus, since
previous cross-sectional amyloid imaging studies have suggested that precuneus
has the highest deposition levels (Mintun et al., 2006) and provided preliminary
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evidence that it may be the most rapid accumulator (Rodrigue et al., 2012)315
among cortical regions. Our specific hypotheses are as follows:
1. The precuneus has the highest amyloid load along stages of amyloid
accumulation.
2. The precuneus accumulates amyloid faster than other cortical regions.
We refer to the progression scores calculated using the DVR images as Aβ-PS.
To test the first hypothesis, we compare the amyloid levels in the precuneus
with other regions at various Aβ-PS values spanning the range observed in our
data set. Our purpose in performing these comparisons is to shed light onto the
temporal ordering of changes in different cortical regions. For each bootstrap
experiment, we average the predicted DVR levels yˆk(s) = aks+ bk within each
ROI to obtain
yˆr(s) =
1
|ROIr|
∑
k∈ROIr
yˆk(s), (19)
where k is the voxel index and r is the ROI index. We then compute the following
statistic for each bootstrap:
T = yˆprecuneus(s)− max
r 6=precuneus
yˆr(s). (20)
We reject the null hypothesis that the amyloid load in the precuneus at Aβ-320
PS = s is not different from other regions at significance level γ if the two-sided
100(1−γ) confidence interval of the test statistic T , computed using the bootstrap
estimates of T , does not contain 0. The smallest value of γ such that the two-
sided 100(1−γ) confidence interval of the test statistic T contains 0 is the p-value
of the test.325
To test the second hypothesis, we pursue a similar approach using the
trajectory slope parameter a. For each bootstrap experiment, we obtain the
average ak per cortical ROI to obtain ar, where r the ROI index. We then
compute the following statistic for each bootstrap:
T = aprecuneus − max
r 6=precuneus
ar. (21)
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The condition for the rejection of the null hypothesis that the rate of amyloid
accumulation in the precuneus is not different from that of other regions is as
described previously.
3. Results
3.1. Simulation330
The Akaike information criterion (AIC) was 39.0× 103 for the LME model,
32.0× 103 for the PS model where C = IK×K , and −1.6× 103 for the PS model
where C = C(ρ), indicating that the PS model where spatial correlations are
modeled fits the data the best. We computed the percentage of variables that
are “correct” by counting the variables whose ground truth values fell within the335
95% confidence interval computed via bootstrapping. For example, for a and
b, a value of 10% indicates that 10% of the biomarkers had a correct estimate
for ak and bk. For α and β, 10% indicates that 10% of the individuals had a
correct estimate for αi and βi. For s, 10% indicates that 10% of the visits had
a correct estimate for sij . Simulation results are presented in Table 3. When340
there are correlations in the data, not modeling them yields inaccurate estimates
for the trajectory slope parameter a, the subject-specific variables αi, βi, and
the progression scores sij . Using the correlation model improves these estimates
significantly.
3.2. Amyloid images345
In our preliminary analysis of the noise spatial correlation structure using
the semivariogram (Cressie and Hawkins, 1980; Bilgel et al., 2015c), we observed
that the rational quadratic had the best fit to the empirical semivariogram
(Inline Supplementary Fig. 1). Rational quadratic also yielded the fit with
largest log-likelihood, and thus was selected as the correlation function for the350
model. AIC was −1.2× 107 for the LME model, −1.1× 107 for the model where
C = IK×K , and −2.0× 107 for the model where C = C(ρ), indicating that the
PS model where spatial correlations are modeled fits the data the best. The
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Table 3: Simulation results. Mean cosine similarity values across 1000 bootstrap experiments
(with standard deviation) and percentage of variable elements that are correct based on 95%
confidence intervals are presented.
C = IK×K C = C(ρ)
Variable Cosine similarity % correct Cosine similarity % correct
a 0.9514± 0.0154 24 0.9821± 0.0073 98
b 0.9998± 0.0001 99 0.9998± 0.0001 98
α 0.1587± 0.0812 18 0.7922± 0.0332 40
β 0.1250± 0.0794 19 0.7835± 0.0339 38
s 0.8017± 0.0443 23 0.9881± 0.0053 85
Figure 3: Estimated trajectory slope parameters ak vs ground truth. Dashed line indicates
x = y. Gray band corresponds to the 95% confidence intervals obtained from bootstrapping.
Estimates are shown in blue if their 95% confidence interval intersects the x = y line, and in
red otherwise. Results from the model where (a) C = IK×K and (b) C = C(ρ).
spatial correlation parameter ρ for the rational quadratic correlation model was
estimated to be 4.5 mm, and λ was estimated to be 0.929. A comparison of the355
PS values obtained from the different correlation models are presented in the
Supplementary Material (Inline Supplementary Fig. 2). Model fitting using 104
subjects with a total of 300 visits each having about 30, 000 brain voxels took
approximately 5 seconds on an Intel Xeon 8-core 3.1 GHz machine with 128 GB
RAM for the case where voxels are assumed to be independent (i.e., C = IK×K).360
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Figure 4: Predicted progression scores sij vs ground truth. Dashed line indicates x = y. Gray
band corresponds to the 95% confidence intervals obtained from bootstrapping. Estimates are
shown in blue if their 95% confidence interval intersects the x = y line, and in red otherwise.
Results from the model where (a) C = IK×K and (b) C = C(ρ).
The following model fitting with C = C(ρ) took approximately 30 minutes per
EM iteration, with convergence achieved in 2 to 6 iterations depending on the
correlation structure.
3.2.1. Comparison of Aβ-PS to mean cortical DVR
We compared the subject-specific variables obtained from model fitting to365
empirical values obtained from mean cortical DVR, which is the widely used
measure for quantifying levels of brain amyloid (Fig. 5). For each individual
with at least two visits, we fit a line to the mean cortical DVR data to estimate
the slope of amyloid accumulation as well as the intercept. The subject-specific
variable αi, which represents the rate of amyloid progression, explained 62% of370
the variability in the empirical slope of amyloid accumulation computed from
longitudinal mean cortical DVR. We observed a much higher correlation between
mean cortical DVR and Aβ-PS (R2 = 0.95 at baseline and 0.96 at last visit).
When plotted against age, mean cortical DVR and Aβ-PS revealed similar
patterns (Fig. 6). The progression as measured using voxelwise DVR data is not375
linearly associated with age, and the Aβ-PS was able to capture this.
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Figure 5: Correlation of estimated subject-specific variables with mean cortical DVR measures.
The line of best fit is shown in blue, and its 95% confidence band in gray. (a) Rate of annual
change in mean cortical DVR vs. α, the predicted rate of change in amyloid progression
score (R2 = 0.62). (b) Intercept of mean cortical DVR vs. β, the progression score intercept
(R2 = 0.48). (c) Mean cortical DVR vs. Aβ-PS at baseline (R2 = 0.95). (d) Mean cortical
DVR vs. Aβ-PS at last visit (R2 = 0.96).
3.2.2. Amyloid trajectories
The trajectory slope parameters ak obtained from the PS model (Fig. 7)
revealed symmetric patterns across the cerebral hemispheres. The precuneus and
frontal lobe showed the greatest increases in DVR with Aβ-PS, smaller increases380
in lateral temporal and temporoparietal regions, and minimal increases in the
occipital lobe and the sensorimotor strip. Voxelwise trajectories are further
illustrated in Fig. 8, which shows the predicted DVR values on the cortical
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Figure 6: (a) Mean cortical DVR and (b) Aβ-PS plotted against age. Longitudinal data points
are connected by lines within each subject. Different colors indicate different subjects.
Figure 7: Slope parameters ak obtained from voxelwise PS model projected onto the cortical
surface. For each unit increase in Aβ-PS, the DVR value at voxel k increases by ak.
surface at three Aβ-PS levels.
In order to better investigate regional trends, we averaged the PS model385
results within each cortical ROI and plotted these ROI averages as a function of
Aβ-PS (Fig. 9). We used bootstrap results to compute 95% confidence bands
for these ROI averages. Based on the 95% confidence band of the precuneus
illustrated in Fig. 9, precuneus appears to be the earliest accumulator and has the
highest amyloid levels through late stages of amyloid accumulation (Aβ-PS≥ 2).390
We present confidence bands for other cortical regions in Fig. 10.
Based on our hypothesis testing procedure, we found that precuneus had the
highest amyloid levels at Aβ-PS values of -0.5, 0, 1, 2, and 3 (all p < 0.01). On
the other hand, while the estimated rate of amyloid accumulation was highest in
the precuneus, this was not statistically significant (p = 0.33). A comparison395
of the levels of amyloid at Aβ-PS= 0 and rates of accumulation across ROIs is
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Figure 8: Predicted DVR levels at Aβ-PS = −0.6 (top), 0.4 (middle row), and 1.5 (bottom).
Figure 9: Regional trajectories as function of Aβ-PS. The PS model was used to make voxelwise
predictions at a range of Aβ-PS values, and these predictions were averaged within each ROI
to obtain regional trajectories. The dashed lines indicate the 95% confidence band obtained
using bootstrap results for the precuneus.
presented in Fig. 11.
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Figure 10: Regional trajectories as function of Aβ-PS. The PS model was used to make
voxelwise predictions at a range of Aβ-PS values, and these predictions were averaged within
each ROI to obtain regional trajectories. The dashed lines indicate the 95% confidence bands for
the cortical regions. Estimated trajectories with their 95% confidence bands are superimposed
on observed longitudinal data (in gray).
3.2.3. Comparison to LME results
The trajectories we obtained using the PS model were consistent with the
results of the LME model (Inline Supplementary Figs. 3, 4). However, the fixed400
effects obtained from the LME model did not describe the observed data as
well as the trajectory slopes obtained from the PS model (Inline Supplementary
Fig. 5). Using the LME model estimates and a bootstrapping procedure similar
to the one we applied for the PS model, we found that the precuneus had the
highest regional amyloid levels compared to other cortical regions at ages 70, 80,405
and 90 (all p < 0.01), but not at age 65 (p = 0.12). Similar to our findings based
on the PS model, the rate of amyloid accumulation was highest in the precuneus,
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Figure 11: Comparison of levels of amyloid at Aβ-PS= 0 and rates of amyloid accumulation
across cortical regions. The intercept parameter b obtained from the PS model was averaged
within each ROI to obtain the regional amyloid levels at Aβ-PS= 0, and the trajectory slope
parameter a was averaged within each ROI to obtain regional rates.
but this was not statistically significant (p = 0.75). A comparison of the levels
of amyloid at the mean baseline age of the sample and rates of accumulation
across ROIs is presented in Inline Supplementary Fig. 6.410
4. Discussion
We presented a statistical model for estimating longitudinal trajectories of
voxelwise neuroimaging data. Our model is based on the concept that age is
not a good metric for disease progression since each individual has his or her
own onset and rate of progression of disease. We accounted for these inter-415
individual differences to temporally align individuals based on their collection of
voxelwise measurements. As a result of this temporal alignment, we obtained
a metric of disease or underlying biological process stage as reflected in the
neuroimaging data, and we call this metric “progression score”. By analyzing
voxelwise neuroimaging data as a function of progression score rather than time,420
we constructed trajectories that better represent changes occurring with disease
stage.
Simulation results showed that the progression score model fits the data
better than the linear mixed effects model, as evidenced by AIC. Furthermore,
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the results showed that modeling spatial correlations is important for extracting
accurate summary scores from data with underlying correlations. In the absence
of correlation modeling when the underlying data are correlated, estimates of
the trajectory slopes a as well as subject-specific variables α, β, and s were
adversely affected. The difference in the subject-specific variables was mainly
due to inaccurate estimates of the prior covariance V . Note that
Cov(yij) = aq
T
ijV qija
T +R, (22)
which explains why both a and V are affected when correlations are not modeled
through the covariance matrix R. This highlights the importance of modeling
spatial correlations in data where such effects are evident, especially in order425
to estimate correct trajectory slopes and individualized progression scores. To
further understand this phenomenon, we conducted simulations (data not pre-
sented) where we duplicated biomarkers with lower signal-to-noise ratios and
repeated model fitting including these duplicate biomarkers. We observed that
the parameter estimates as well as the PS values were biased if we assumed430
independence across biomarkers. This might be because the model interprets
each of the duplicated biomarkers as a separate piece of evidence towards the
computation of individual progression scores. However, when we included a
proper noise correlation model, we were able to recover our original results on
the collection of unique biomarkers.435
The proposed EM framework simplifies the estimation of spatial correlation
parameters, and accurately estimates the trajectory parameters a and b as well
as predicting the progression scores s. The performance of the fitting procedure
in predicting α and β is worse than for s. This may be due to the modeling of α
and β as random variables that do not directly contribute to the observations440
y. We observed a similar pattern in the amyloid data: the agreement between
estimated Aβ-PS and mean cortical DVR was greater than the agreement between
estimated α and the rate of change of mean cortical DVR per individual. This
suggests that the progression scores are more reliable than the subject-specific
variables. Aβ-PS was highly correlated with mean cortical DVR, a widely used445
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measure for quantifying PiB-PET scans and assessing longitudinal change. This
indicates that Aβ-PS is a meaningful score extracted from voxelwise imaging
data. Unlike mean cortical DVR, there are no a priori assumptions regarding
which regions or voxels should be included in the computation of Aβ-PS. This
property of PS allows for the discovery of new patterns in longitudinal data.450
Trajectories obtained from the PS model captured a wider dynamic range of
DVR values and had a better fit to the observed data compared to the trajectories
obtained using the LME model fixed effects. This difference between the PS
and LME models underscores the fact that age is not an appropriate metric for
staging amyloid accumulation. By aligning individuals based on their amyloid455
scans, the PS model enables a better temporal metric of amyloid staging.
Aβ-PS allows for the exploration of longitudinal voxelwise trajectories within
a hypothesis testing framework due to its underlying statistical model. Our
results suggest that the precuneus exhibits the earliest cortical amyloid changes,
but that its rate of amyloid accumulation does not differ significantly from other460
cortical regions. Based on a qualitative evaluation of our estimated trajectories,
we found that amyloid accumulation in the precuneus is followed by cingulate
and frontal cortices, then by lateral parietal cortex, followed by insula and lateral
temporal cortex. We observed minimal amyloid accumulation in visual cortex,
hippocampal formation and the sensorimotor strip, which agrees with previous465
reports that these regions accumulate amyloid in later stages of AD (Braak and
Braak, 1991). Previous reports have highlighted precuneus as an early amyloid
accumulator (Mintun et al., 2006; Rodrigue et al., 2012) as well as frontal,
cingulate, and parietal regions (Jack et al., 2008). Contrary to our finding
highlighting precuneus as the earliest cortical accumulator, a study of cognitively470
normal adults found that the right medial frontal cortex accumulates amyloid the
earliest, closely followed by bilateral precuneus based on cross-sectional voxelwise
analyses (Villeneuve et al., 2015). We presented regional trajectories averaged
bilaterally in this work; however, hemisphere-specific trajectories were consistent
with our bilaterally-averaged trajectories and we did not observe that medial475
frontal cortex precedes precuneus. Further studies with larger samples will be
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instrumental in elucidating the regional progression of amyloid accumulation.
One of the strengths of our model for the progression scores s is that there
are no a priori assumptions on the global form of s(t), which can be thought
of as an underlying function that describes the evolution of progression score480
over time. Instead, the model makes linear local approximations to s(t) per
individual. The linear form we use makes the EM approach analytically tractable
and enables the discovery of the global form of s(t). On the other hand, the
linear relationship we assume between s and t is also a limitation since it may be
an oversimplification over long follow-up durations. In order to capture dynamics485
over longer periods more accurately, it is necessary to investigate the relationship
between the progression scores s and time t, and select an appropriate function
to link these variables.
Another limitation of our model is the assumption of linear biomarker trajec-
tories. This assumption is not reflective of the fact that voxelwise DVR has a490
theoretical minimum of 1 (while in practice, there are DVR values lower than 1
due to noise). Furthermore, several studies of longitudinal amyloid deposition
have found evidence for a ceiling effect in amyloid deposition in late AD, sug-
gesting a sigmoid trajectory for amyloid levels (Villemagne et al., 2013; Villain
et al., 2012). Our use of a linear rather than sigmoid trajectory inevitably results495
in inaccuracies in PS calculation for individuals whose voxelwise data lie along
the plateaus of the sigmoid in reality. The linear trajectory assumption may
also prevent us from characterizing subtler differences in the temporal ordering
of the onset of amyloid accumulation across different regions. However, linear
trajectories, unlike sigmoid trajectories, yield closed-form update equations for500
trajectory parameters, greatly facilitating the model fitting procedure.
The spatial covariance functions we used in our analyses are covariance
functions of strictly stationary isotropic processes. The underlying spatial noise
process is affected by the PET scanner, image reconstruction algorithm, ra-
diotracer delivery and binding in different brain regions, kinetic parameter505
estimation algorithm, and registration methods used to bring all scans in align-
ment. To accurately model these influences on noise, complex noise spatial
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covariance models are needed. In this work, we made simplifying assumptions on
the noise properties to facilitate the study of longitudinal trajectories of amyloid
images. As a result of these simplifications, our model does not accurately510
capture noise properties; however, by eliminating the inaccurate assumption of
independence across voxels, our approach improves the accuracy of the estimated
trajectories and progression scores. Refined spatial noise models incorporating
non-stationarity and anisotropy may further improve the estimation accuracy.
Our model can be applied to studying higher resolution images. To reduce515
computational memory burden, it may be necessary to impose sparsity on the
spatial correlation matrix, which can be done by imposing a correlation value
of 0 at large distances. The sparsity property of the correlation matrix can be
taken advantage of to yield Cholesky decompositions using less memory and
time.520
In conclusion, the progression score model allows for extracting summary
scores from longitudinal data for each scan. In this work, we have extended the
progression score model proposed by Jedynak et al. (2012) to voxelwise imaging
data by accounting for spatial correlations and enabling efficient handling of the
large number of voxels through the EM framework. The incorporation of a prior525
on subject-specific variables allowed for the inclusion of individuals with a single
visit in the model. Our method can be extended to the analysis of other types of
imaging data, and in cases where a summary score such as mean cortical DVR
is not available, the progression score estimates can be highly informative for
progression staging.530
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Appendix A.
Proposition A.1.
f(u˜i | yi;θ′) ∝ Φ(u˜i; uˆ′i,Σ′i), (A.1)
where Φ( · ;µ,Σ) denotes the probability density function of a multivariate normal
with mean µ and covariance matrix Σ,
uˆ′i =
∑
j
Z ′Tij R
′−1Z ′ij + V
′−1
−1∑
j
Z ′Tij R
′−1(yij − b′) + V ′−1m′
 ,
(A.2)
and Σ′i =
(∑
j Z
′T
ij R
′−1Z ′ij + V
′−1
)−1
is a covariance matrix.
Proof. Independence across visits allows us to write
f(yi | u˜i;θ′) =
∏
j
f(yij | u˜i;θ′)
=
∏
j
Φ(yij ;Z
′
iju˜i + b
′, R′)
∝ exp
−12
u˜Ti
∑
j
Z ′Tij R
′−1Z ′ij
 u˜i
−2
∑
j
(yij − b′)TR′−1Z ′ij
 u˜i
 , (A.3)
where we have ignored the terms that do not depend on u˜i.540
By Bayes’ rule,
f(u˜i | yi;θ′) ∝ f(yi | u˜i;θ′)f(u˜i;θ′) (A.4)
∝ exp
−12
u˜Ti
∑
j
Z ′Tij R
′−1Z ′ij + V
′−1
 u˜i
−2
∑
j
(yij − b′)TR′−1Z ′ij +m′TV ′−1
 u˜i
 (A.5)
∝ Φ(u˜i; uˆi,Σ′i) (A.6)
Below we derive the EM algorithm update equations given in Section 2.3:
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Solving for the intercept parameter b
The value of b that solves ∂Q∂b = R
−1∑
i,j(yij − Zijuˆ′i − b) = 0 is given by545
b =
1∑
i vi
∑
i,j
(yij − Zijuˆ′i)
=
1∑
i vi
∑
i,j
(
yij − as′ij
)
. (A.7)
Plugging in the expression for a from Equation A.9 yields
b =
(∑
i,j yij
)(∑
i,j q
T
ijΣ
′
iqij + s
′2
ij
)
−
(∑
i,j yijs
′
ij
)(∑
i,j s
′
ij
)
(
∑
i vi)
(∑
i,j q
T
ijΣ
′
iqij + s
′2
ij
)
−
(∑
i,j s
′
ij
)2 . (A.8)
Solving for the slope parameter a
The value of a that solves ∂Q∂a = R
−1
[∑
i,j(yij − b)s′ij − a
(∑
i,j q
T
ijΣ
′
iqij + s
′2
ij
)]
= 0
is given by
a =
1∑
i,j q
T
ijΣ
′
iqij + s
′2
ij
∑
i,j
(yij − b)s′ij . (A.9)
Plugging in the expression for b from Equation A.7 yields
a =
(
∑
i vi)
(∑
i,j yijs
′
ij
)
−
(∑
i,j yij
)(∑
i,j s
′
ij
)
(
∑
i vi)
(∑
i,j q
T
ijΣ
′
iqij + s
′2
ij
)
−
(∑
i,j s
′
ij
)2 . (A.10)
Solving for the subject-specific variable mean parameter m
The value of m that solves ∂Q∂m = −
∑
i V
−1m+
∑
i V
−1uˆ′i = 0 is given by
m =
1
n
∑
i
uˆ′i. (A.11)
Solving for the subject-specific variable variance parameter ν550
We use numerical optimization to estimate ν:
ν = arg max
ν
Q(θ,θ′) (A.12)
= arg min
ν
∑
i
(
log |V |+ (uˆ′i −m)TV −1(uˆ′i −m) + Tr
(
V −1Σ′i
))
.(A.13)
We can reconstruct V by undoing the log-Cholesky parametrization steps using
the estimated parameter vector ν = [ν1, ν2, ν3]
T as
V =
eν1 0
ν2 e
ν3
eν1 ν2
0 eν3
 . (A.14)
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Solving for the noise covariance parameters λ and ρ
If C = IK×K (i.e. ρ = 0 and fixed), then the diagonal elements λk of Λ can555
be estimated as:
λk =
√
1∑
i vi
∑
i,j
[
(yijk − aks′ij − bk)2 + a2kqTijΣ′iqij
]
. (A.15)
If C is not fixed to be the identity matrix, then in general it is not possible to
obtain closed-form solutions for λ and ρ and we must use numerical optimization
over Q. When λ is a high-dimensional vector, this is not feasible. Therefore,
we simplify the parametrization of the noise covariance matrix R as R(λ, ρ) =560
λ2ΛˆC(ρ)Λˆ, where we now consider Λˆ as a fixed diagonal matrix with positive
diagonal entries. We fix Λˆ at the estimate of Λ from the model with C = IK×K .
ρ is the correlation matrix parameter as defined previously, and λ > 0 is a scaling
parameter. Now we need to perform numerical optimization over Q to estimate
only two parameters:565
λ, ρ = arg max
λ,ρ
Q(θ,θ′). (A.16)
Note that since the EM algorithm does not require the maximization of Q(θ,θ′)
but simply requires an increase in this function with each iteration, performing
numerical optimization until convergence is not necessary.
Proposition A.2. Consider the model given in Section 2.1.5 with θ = {m, V,a,b, R}.
The reparametrization θ∗ =
wm+
0
z
 , w2V, 1wa,b− zwa, R
, where w, z ∈570
R, w 6= 0 yields an equivalent model.
Proof. The incomplete log-likelihood is
log f(y;θ) =
1
2
∑
i
(log |2piΣi| − log |2piV | − vi log |2piR|)
−1
2
∑
i,j
(yij − b)TR−1(yij − b)
−1
2
∑
i
mTV −1m+
1
2
∑
i
uˆTi Σ
−1
i uˆi. (A.17)
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Here, we consider the case where z = 0 for algebraic simplicity. For the
reparameterized model, we obtain uˆ∗i = wuˆi and Σ
∗
i = w
2Σi. Therefore, each
of the terms in log f(y;θ∗) remain the same as those in log f(y;θ), yielding575
log f(y;θ∗) = log f(y;θ).
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Inline Supplementary Figure 1: Preliminary analysis of the noise spatial correlation structure
using the semivariogram. The empirical semivariogram computed using the residuals from
the model where C = IK×K is shown in blue. We fitted the semivariograms corresponding
to the exponential, Gaussian, rational quadratic, and spherical correlation structures listed
in Table 1 to the empirical semivariogram. The rational quadratic function had the best fit
to the empirical curve based on the sum of squared error of the fitted semivariogram over a
100 mm distance calculated using 30 equidistant points.
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Inline Supplementary Figure 2: Bland-Altman plots comparing Aβ-PS values obtained using
different spatial correlation models. We fitted the model using the “no correlation” structure
(C = IK×K) and four spatial correlation structures (exponential, Gaussian, rational quadratic,
and spherical). We then used Bland-Altman plots to assess the differences in PS computed
using these correlation structures. In the Bland-Altman plots, the x-axis is the average of the
PS values computed using the two methods being compared, and the y-axis is the difference.
The labels above and to the left of the figures describe the spatial correlation structures being
compared. Each blue dot corresponds to a visit. The solid black line indicates the mean
difference between PS values computed using the methods, and the dashed red lines indicate
its 95% confidence band. The Bland-Altman plots indicate that the “no correlation”, Gaussian,
and spherical structures yield similar PS values. Furthermore, the exponential and rational
quadratic structures also yield similar PS values, but these differ from those obtained using
the other three structures.
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Inline Supplementary Figure 3: Slope parameters ηk (fixed effects) obtained from voxelwise
LME model projected onto the cortical surface. DVR value at voxel k increases by ηk per year
on average.
Inline Supplementary Figure 4: Regional trajectories obtained from the LME model as function
of age. The LME model was used to make voxelwise predictions at a range of age values based
on the estimated fixed effects, and these predictions were averaged within each ROI to obtain
regional trajectories. The dashed lines indicate the 95% confidence bands for the cortical
regions.
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Inline Supplementary Figure 5: Regional trajectories obtained from the LME model as function
of age. The LME model was used to make voxelwise predictions at a range of age values based
on the estimated fixed effects, and these predictions were averaged within each ROI to obtain
regional trajectories. The dashed lines indicate the 95% confidence bands for the cortical
regions. Estimated trajectories with their 95% confidence bands are superimposed on observed
longitudinal data (in gray).
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Inline Supplementary Figure 6: Comparison of levels of amyloid at age 77 (the mean baseline
age of the sample) and rates of amyloid accumulation across cortical regions using results of
the LME model. We used the fixed effect estimates to obtain voxelwise amyloid levels at age
77 as yˆk = ηk × 77 + γk, and averaged yˆk within each ROI to obtain regional amyloid levels at
age 77. The fixed effects ηk were averaged within each ROI to obtain regional rates.
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